Pharmacogenetics of alcohol-dependence

Psychopharmacogenetics

Volumn , Issue , 2006, Pages 177-201

  Gorwood, Philip ^a   Schumann, Gunter ^b   Treutlein, Jens ^b   Adès, Jean ^a  

^a HÔPITAL LOUIS MOURIER   (France)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34248386413     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-34577-2_7     Document Type: Chapter

References (149)

1. Adinoff B, Martin P. R., Bone G. H. A., Eckardt M. J., Roehrich L., George D. T. et al., 1990, Hypothalamic-pituitary-adrenal axis functioning and cerebrospinal fluid corticotropin releasing hormone and corticotropin levels in alcoholics after recent and long-term abstinence, Arch Gen Psychiatry. 47, pp. 325-330.
2. Akil H, Owens C, Gutstein H, et al., 1998, Endogenous opioids: overview and current issues, Drug and Alcohol Dependence. 51:127-140.
3. Anton R. F., Moak D. H., Latham P. K., Waid L. R., Malcolm R. J., Dias J. K. et al., 2001, Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism, J Clin Psychopharmacol. 21:72-77.
4. Balldin J. I., Berggren U. C., Lindstedt G., 1992, Neuroendocrine evidence for reduced dopamine receptor sensitivity in alcoholism, Amc Clin Exp Res. 16:71-74.
5. Baumgarten H. G., Grozdanovic Z., 1997, Anatomy of central serotoninergic projection systems. In: Baumgarten HG, Göthert (Hrsg) Handbook of experimental pharmacology, Vol 129. Serotoninergic neurons and 5-HT receptors in the ZNS. Springer, Berlin, Heidelberg; 41-89.
6. Befort K., Filliol D., Decaillot F. M., Gaveriaux-Ruff C., Hoehe M. R., Kieffer B. L., 2001, A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs recptor signaling, J Biol Chem. Feb. 2:276(5):3130-7.
7. Bell S. M., Reynolds J. G., Thiele T. E., Gan J, Figlewicz D. P., Woods S. C., 1998, Effects of third intracerebroventricular injections of corticotropin-releasing factor (CRF) on ethanol drinking and food intake. Psychopharmacology, Berl, 139:128-135.
8. Bergen A., Kokoszka J., Peterson R., Long J., Virkkunen M., Linnoila M. et al., 1997, Mu-opioid receptor gene variants: lack of association with alcohol dependence, Mol Psychiatry. 2:490-494.
9. Berman J. D., Cook D. M., Buchman M. and Keith L. D., 1990, Diminished adrenocorticotropin response to insulin-induced hypoglycemia in nondepressed, actively drinking male alcoholics, J Clin Endocrinol Metab. 71: pp. 712-717.
10. Berrettini W., Hoehe M., Ferraro T., DeMaria P., Gottheil E., 1997, Human μ opioid receptor gene polymorphisms and vulnerability to substance abuse, Addict Biol. 2:303-308.
11. Bond C., LaForge K., Tian M., Melia D., Zhang S., Borg L. et al., 1998, Single-nucleotide polymorphism in the human μ opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction, Proc Natl Acad Sci. 95:9608-9613.
12. Bosron W. F., Li T.-K., 1986, Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism, Hepatology. 6:502-510.
13. Brady K. T., Sonne S. C., 1999, The role of stress in alcohol use, alcoholism treatment, and relapse, Alcohol Res Health. 23(4):263-71.
14. Buck K. J., Metten P., Belknap J. K., et al., 1997, Quantitative trait loci involved in genetic predisposition to acute alcohol withdrawal in mice, J Neurosci. 17:3946-3955.
15. Chen S. Y., Liu T. Y., Shun C. T., Wu M. S., Lu T. H., Lin J. T., Sheu J. C., Santella R. M., Chen C. J., 2004, Modification effects of GSTM1, GSTT1 and CYP2E1 polymorphisms on associations between raw salted food and incomplete intestinal metaplasia in a high-risk area of stomach cancer, Int J Cancer. Feb. 10;108(4):606-12.
16. Cheung H. H., Gurd J. W., 2001, Tyrosine phosphorylation of the N-methyl-D-aspartate receptor by exogenous and postsynaptic density-associated Src-family kinases, J Neurochem. 78:524-534.
17. Chick J., Anton R., Checinski K., Croop R., Drummond D. C., Farmer R. et al., 2000, A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse, Alcohol Alcoholism. 35:587-593.
18. Choi J. Y., Abel J., Neuhaus T., Ko Y., Harth V., Hamajima N., Tajima K., Yoo K. Y, Park S. K., Noh D. Y., Han W., Choe K. J., Ahn S. H., Kim S. U., Hirvonen A., Kang D., 2003, Role of alcohol and genetic polymorphisms of CYP2E1 and ALDH2 in breast cancer development, Pharmacogenetics. Feb; 13(2):67-72.
19. Cohen C., Perrault G., Voltz C., Steinberg R. and Soubrie P., 2002, SR141716, a central cannabinoid (CB (1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats, Behavioral Pharmacology. 13:5-6, pp. 451-463.
20. Collingridge G. L., Lester R. A., 1989, Excitatory amino acid receptors in the vertebrate central nervous system, Pharmacol Rev. 41:143-210.
21. Comings D. E., Blum K., 2000, Reward deficiency syndrome: genetic aspects of behavioral disorders, Prog Brain Res. 126:325-41.
22. Copper J. R., Bloom F. E., Roth R. H., 1991, The biochemical basis of Neuropharmacology. 6th edn., Oxford University Press, New York.
23. Costa A., Bono G., Martignoni E., Merlo P., Sances G. and Nappi G., 1996, An assessment of hypothalamo-pituitary-adrenal axis functioning in non-depressed, early abstinent alcoholics, Psychoneuroendocrinology. 21, pp. 263-275.
24. Crowley J., Oslin D., Patkar A., Gottheil E., DeMaria P., O'Brien C. et al., 2003, A genetic association study of the μ opioid receptor and severe opioid dependence, Psychiatr Genet. Sep; 13(3):169-73.
25. Deadwyler SA., Hampson RE., Mu J., Whyte A., Childers S., 1995, Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J Pharmacol Exp Ther. 273(2):734-43.
26. Di Chiara G., 1995, The rule of dopamine in drug abuse viewed from the perspective of its role in motivation, Drug Alc Dependence. 38:95-137.
27. Di Chiara G., 1997, Alcohol and Dopamine, Alcohol Health und Research World. 21:108-113.
28. Ehrenreich H., Schuck J., Stender N., Pilz J., Gefeller O., Schilling L. et al., 1997, Endocrine and hemodynamic effects of stress versus systemic CRF in alcoholics during early and medium term abstinence, Alcohol Clin Exp Res. 21, pp. 1285-1293.
29. Enomoto N., Takada A. and Date T., 1991, Genotyping of the aldehyde dehydrogenase 2 (ALDH2) gene using the polymerase chain reaction: Evidence for single point mutation in the ALDH2 gene of ALDH2 deficiency, Gastroenterol Jpn. 26:440-447.
30. Fábián G., 2001, Heterotrimeric G-proteins and their role in opioid receptor function, Acta Biol Szeged. 45:13-21.
31. Fehr C., Rademacher B. L., Buck K. J., 2003, Evaluation of the glutamate decarboxylase genes Gad1 and Gad2 as candidate genes for acute ethanol withdrawal severity in mice, Prog Neuropsychopharmacol Biol Psychiatry. 27:467-472.
32. Fils-Aime M. L., Eckhardt M. J., George D. T., et al., 1996, Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindolacetic acid levels than late-onset alcoholics, Arch Gen Psychiatry. 53:211-216.
33. Forth W., 1996, Allgemeine und spezielle Pharmakologie und Toxikologie, 7th edn., Spektrum Verlag Heidelberg, Germany.
34. Franke P., Wang T., Nöthen M., Knapp M., Neidt H., Albrecht S. et al., 2001, Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence, Am J Med Genet. 105:114-119.
35. Froehlich J. C., 1997, Opioid Peptides, Alcohol Health Res. World 21:132-136.
36. Gelernter J., Kranzler H., Cubells J., 1999, Genetics of two μ opioid receptor gene (OPRM1) exon 1 polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects, Mol Psychiatry. 4:476-483.
37. Gilligan S. B., Reich T., Cloninger C. R., 1987, Etiologic heterogeneity in alcoholism, Genet Epidemiol. 4(6):395-414.
38. Goedde H., and Agarwal D., 1987. Polymorphism of aldehyde dehydrogenase and alcohol sensitivity, Enzyme. 37, pp. 29-44.
39. Goedde H. W., Agarwal D. P., Fritze G., Meier-Tachmann D., Singh S., Beckmann G., Bhatia K., Chen L. Z., Fang B., Lisker R., et al., 1992, Distribution of ADH2 and ALDH2 genotypes in different populations. Hum Genet 88:344-346.
40. Goldman D., 1995, Candidate genes in alcoholism, Clin Neurosci. 3(3):174-81.
41. Grosch S., Niederberger E., Lotsch J., Skarke C., Geisslinger G., 2001, A rapid screening method for a single nucleotide polymorphism (SNP) in the human MOR gene, Br J Clin Pharmacol. Dec; 52(6):711-4.
42. Gscheidel N., Sander T., Wendel B., Heere P., Schmidt L. G., Rommelspacher H., Hoehe M. R., Samochowiec J., 2000, Five exon 1 variants of μ opioid receptor and vulnerability to alcohol dependence, Pol J Pharmacol. Jan-Feb; 52(1):27-31.
43. Harada S., Agarwal D. P., Goedde H. W., 1981, Aldehyde dehydrogenase deficiency as cause of facial flushing reaction to alcohol in Japanese, Lancet. 2:982.
44. Hashimoto Y., Nakayama T., Futamura A., Omura M., Nakarai H., Nakahara K., 2002, Relationship between genetic polymorphisms of alcohol-metabolizing enzymes and changes in risk factors for coronary heart disease associated with alcohol consumption, Clin Chem. Jul; 48(7):1043-8.
45. Hayashi S., Watanabe J., Kawajiri K., 1991, Genetic polymorphisms in the 5' flanking region change transcriptional regulation of the human cytochrome p450 IIEI gene, J Biochem. 110:559-65.
46. Heinz A., 2000, Das dopaminerge Verstärkungssystem: Funktion, Interaktion mit anderen Neurotransmittersystemen und psychopathologische Korrelate. In: Hippius H, Sass H, Sauer H (Hrsg) Monographien aus dem Gesamtgebiet der Psychiatrie. Steinkopff, Darmstadt.
47. Heinz A., Goldman D., Jones D. W., Palmour R., Hommer D., Gorey J. G., Lee K. S., Linnoila M., Weinberger D. R., 2000, Genotype influences in vivo dopamine transporter availability in human striatum, Neuropsychopharmacology. 22:133-9.
48. Heinz A., Batra A., 2003, Neurobiologie der Alkoholabhängigkeit. In: Brandt T., Cohen R., Helmchen H., Schmidt L. R. (Hrsg) Psychiatrie, Neurologie, Klinische Psychologie Grundlagen, Methoden, Ergebnisse. Kohlhammer, Stuttgart.
49. Heinz A., Dettling M., Kuhn S., et al., 1995, Blunted growth hormone response is associated with early relapse in alcohol-dependent patients, Alc Clin Exp Res. 19:62-65.
50. Hernandez-Avila C., Wand G., Luo X., Gelernter J., Kranzler H., 2003, Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1), Am J Med Genet. 118 B: 60-65.
51. Herz A., 1997, Endogenous opioid systems and alcohol addiction, Psychopharmacology. 129:99-111.
52. Hoehe M. R., Kopke K., Wendel B., Rohde K., Flachmeier C., Kidd K. K.et Al., 2000, Sequence variability and candidate gene analysis in complex disease: association of μ opioid receptor gene variation with substance dependence. 9:895-908.
53. Hsu L. C., Tani K., Fujiyoshi T., Kurachi K., Yoshida A., 1985, Cloning of cDNAs for human aldehyde dehydrogenases 1 and 2. Proc Natl Acad Sci USA. 82:3771-3775.
54. Hubbell C. L., Abelson M. L., Burkhardt C. A., Herlands S. E., Reid L. D., 1988, Constant infusions of morphine and intakes of sweetened ethanol solution among rats, Alcohol. Sep-Oct; 5(5):409-15.
55. Inder W. J., Joyce P. R., Ellis M. J., Evans M. J., Livesey J. H and Donald R. A., 1995, The effects of alcoholism on the hypothalamic-pituitary- adrenal axis: Interaction with endogenous opioid peptides, Clin Endocrinol. 43 pp. 283-290.
56. Johnson B. A., Ait-Daoud N., Prihoda T. J., 2000, Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res. 24(5):737-42.
57. Johnson R., Nagoshi C., Schwitters S., Bowman K., Ahern F. and Wilson J., 1984, Further investigation of racial/ethnic differences and of familial resemblances in flushing response to alcohol, Behavior Genetics. 14, pp. 171-178.
58. Kessova I., Cederbaum A. I., 2003, CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury, Curr Mol Med. Sep; 3(6):509-18.
59. King A. C., Volpicelli J. R., Frazer A., O'Brien C. P., 1997, Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence, Psychopharmacology. 129:15-22.
60. Knudsen G. M., Christensen H., Berild D., Melgaard B., Kirkegaard C. and Hasselbalch H., 1987, Discordance between the cortisol response to insulin-hypoglycemia and 30-minute ACTH stimulation test in chronic alcoholic men, Alcohol Clin Exp Res. 11, pp. 323-325.
61. Koob G. F., Le Moal M., 1997, Drug abuse: hedonic homeostatic dysregulation, Science. 278:52-58.
62. Kranzler H., Modesto-Lowe V., VanKirk J., 2000, Naltrexone vs nefazadone for treatment of alcohol dependence, Neuropsychopharmacology. 22:493-503.
63. Kranzler H. R., Gelernter J., O'Malley S., Hernandez-Avila C. A., Kaufman D., 1998, Association of alcohol or other drug dependence with alleles of the μ-Opioid Receptor Gene (OPRMI), Alcoholism: Clin Exp Res. 22:1359-1362.
64. Kranzler H. R., Pierucci-Lagha A., Feinn R., Hernandez-Avila C., 2003, Effects of ondansetron in early-versus late-onset alcoholics: a prospective, open-label study, Alcohol Clin Exp Res. Jul; 27(7):1150-5.
65. Kranzler H. R., Wesson D. R., Billot L., 2004, DrugAbuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial, Alcohol Clin Exp Res. Jul; 28(7):1051-9.
66. Kreek M. J., 1996, Opiates, opioids and addiction, Mol Psychiatry. 1:232-254.
67. Kruger H., Wilce P. A., Shanley B. C., 1993, Ethanol and protein kinase C in rat brain, Neurochem Int. 22:575-581.
68. Krystal J. H., Cramer J. A., Krol W. F., Kirk G. F., Rosenheck R. A., 2001, Veterans Affairs Naltrexone Cooperative Study G (2001). Naltrexone in the treatment of alcohol dependence, New Engl J Med. 345:1734-1739.
69. Kumari M., Ticku M. K., 2000, Regulation of NMDA receptors by ethanol, Prog Drug Res. 54:152-189.
70. LaForge K. S., Shick V., Spangler R., Proudnikov D., Yuferov V., Lysov Y., Mirzabekov A., Kreek M. J., 2000, Detection of single nucleotide polymorphisms of the human μ opioid receptor gene by hybridization or single nucleotide extension on custom oligonucleotide gelpad microchips: potential in studies of addiction, Am J Med Genet. Oct. 9; 96(5):604-15.
71. Lappalainen J., Long J. C., Eggert M., et al., 1998, Linkage of antisocial alcoholism to the serotonin 5-HT1B receptor gene in 2 populations, Arch Gen Psychiatry. 55:989-994.
72. Lawford B. R., Young R. M., Rowell J. A., Qualichefski J., Fletcher B. H., Syndulko K., Ritchie T., Noble E. P., 1995, Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele, Nat Med. Apr; 1(4):337-41.
73. Le Foll B., Goldberg SR., 2004, Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences, Neuroreport. Sep. 15; 15(13):2139-43.
74. Le Foll B., Schwartz J. C., Solokoff P., 2000, Dopamine D3-Receptor agents as potenzial new medication for drug addiction. Eur Psychiatry. 15:140-146.
75. Lesch K. P., Bengel D., Heils A., et al., 1996, Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region, Science. 274:1527-1531.
76. Lotsch J., Skarke C., Grosch S., Darimont J., Schmidt H., Geisslinger G., 2002b, The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine, Pharmacogenetics. Jan; 12(1):3-9.
77. Lotsch J., Zimmermann M., Darimont J., Marx C., Dudziak R., Skarke C., Geisslinger G., 2002a, Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?, Anesthesiology. Oct; 97(4):814-9.
78. Lovallo W. R., Dickensheets S. L., Myers D. A., Thomas D. L. and Nixon S. J, 2000, Blunted stress cortisol response in abstinent alcoholic and polysubstance-abusing men, Alcohol Clin Exp Res. 24 pp. 651-658.
79. Lovinger D. M., 1997, Serotonińs role in alcohoĺs effects on the brain, Alcohol Health & Research World. 21:114-120.
80. Lovinger D. M., White G. and Weight F. F., 1989, Ethanol inhibits NMDA-activated ion current in hippocampal neurons, Science. 243:1721-1724.
81. Lovinger D. M., Zhou Q., 1994, Alcohols potentiate ion current mediated by recombinant 5-HT3RA receptors expressed in a mammalian cell line, Neuropharmacology. 33:1567-1572.
82. Madeira and Paula-Barbosa M. M., 2002, Effects of alcohol on the synthesis and expression of hypothalamic peptides, Brain Res Bull. 48 pp. 3-2.
83. Mansvelder H. D., McGehee D. S., 2002, Cellular and synaptic mechanisms of nicotine addiction, J Neurobiol. 53:606-617.
84. Mascia M. P., Trudell J. R., Harris R. A., 2000, Specific binding sites for alcohol and anesthetics on ligand-gated ion channels, Proc Natl Acad Sci USA. 97:9305-9310.
85. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., Bonner T. I., 1990, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature. 346:561-4.
86. McKernan R. M., Whiting P. J., 1996, Which GABAA-receptor subtypes really occur in the brain?, Trends in Neuroscience. 19:139-143.
87. Michaelis E. K., 1998, Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging, Prog Neurobiol. 54:369-415.
88. Mihic S., Harris A.., 1997, GABA and the GABAA - receptor. Alcohol Health and Research World. 21:127-131.
89. Monteiro M. G., 2001, A World Health Organization perspective on alcohol and illicit drug use and health, Eur Addict Res. Aug; 7(3):98-103.
90. Monteiro M. G., Klein J. L. and Schuckit M. A., 1991, High levels of sensitivity to alcohol in young adult Jewish men: A pilot study, J Stud Alcohol. 52:464-469.
91. Monti P. M., Rohsenow D. J., Swift R. M., Gulliver S. B., Colby S. M., Mueller T. I. et al., 2001, Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes, Alcoholism: Clin Exp Res. 25:1634-1647.
92. Morris P. L., Hopwood M., Whelan G., Gardiner J., Drummond E., 2001, Naltrexone for alcohol dependence: a randomized controlled trial, Addiction. 96:1565-1573.
93. Naranjo C. A., Knoke D. M., 2001, The role of selective serotonin reuptake inhibitors in reducing alcohol consumption, J Clin Psychiatry. 62 Suppl 20:18-25.
94. Nevo I., Hamon M., 1995, Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism, Neurochem. Int. 26:305-336.
95. Nie Z., Madamba S. G., Siggins G. R., 1994, Ethanol inhibits glutamatergic neurotransmission in nucleus accumbens neurons by multiple mechanisms, J. Pharmacol. Exp. Ther. 271:1566-1573.
96. Nille U., 2000, Zur Neurobiologie des Alkoholismus, Abhängigkeiten. 3:27-31.
97. Nomura F., Itoga S., Uchimoto T., Tomonaga T., Nezu M., Shimada H., Ochiai T., 2003, Transcriptional activity of the tandem repeat polymorphism in the 5'-flanking region of the human CYP2E1 gene, Alcohol Clin Exp Res. Aug; 27 (8 Suppl):42S-46S.
98. O'Malley S. S., Jaffe A. J., Chang G., Schottenfeld R. S., Meyer R. E., Rounsaville B., 1992, Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 49:881-887.
99. Oslin D., Liberto J. G., O'Brien J., Krois S., Norbeck J., 1997, Naltrexone as an adjunctive treatment for older patients with alcohol dependence, Am J Geriatr Psychiatry. 5:324-332.
100. Oslin D. W., Berrettini W., Kranzler H. R., Pettinati H., Gelernter J., Volpicelli J. R., O'Brien C. P., 2003, A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients, Neuropsychopharmacology. 28(8):1546-52.
101. Pandey S. C., 1998, Neuronal signaling systems and ethanol dependence, Mol Neurobiol. 17:1-15.
102. Pastino G. M., Flynn E. J., Sultatos L. G., 2000, Genetic polymorphisms in ethanol metabolism: issues and goals for physiologically based pharmacokinetic modeling, Drug Chem Toxicol. 23:179-201.
103. Raimondi S., Benhamou S., Coutelle C., Garte S., Hayes R., Kiemeney L., Lazarus P., Marchand L. L., Morita S., Povey A., Romkes M., Zijno A., Taioli E., 2004, Association of metabolic gene polymorphisms with alcohol consumption in controls, Biomarkers. Mar-Apr; 9(2):180-9.
104. Rhee MH, Bayewitch M, Avidor-Reiss T, Levy R, Vogel Z., 1998, Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J Neurochem. Oct; 71:1525-34.
105. Robinson T. E., Berridge K. C., 1993, The neural basis of drug craving: anincentiv-sensitization theory od addiction, Brain Res Rev. 18:247-291.
106. Roivainen R., Hundle B., Messing R. O., 1994, Proteinkinase C and adaption to ethanol. In: Jansson B, Jornvall H, Rydberg U, Terenius L, Vallee BL (Hrsg) Toward a Molecular Basis of Alcohol Use and Abuse. Birkhäuser, Basel 29-38.
107. Rommelspacher H., Raeder C., Kaulen P., et al., 1992, Adaptive changes of dopamine-D2-Receptors in rat brain following ethanol withdrawal: a quantitative autoradiographic investigation, Alcohol. 9:1-8.
108. Rommelspacher H., Smolka M., Schmidt L., Samochowiec J., Hoehe M. R., 2001, Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals, Alcohol. 24:129-135.
109. Samochowiec J., Kucharska-Mazur J., Kaminski R., Smolka M., Rommelschpacher H., Wernicke C., Tymicz A., Schimdt L. G., 2002, Norepinephrine transporter gene polymorphism is not associated with susceptibility to alcohol dependence. Psychiatry Res. Aug. 30;111 (2-3):229-33.
110. Sander T., Gscheidel N., Wendel B., Samochowiec J., Smolka M., Rommelspacher H. et al., 1998, Human mu-opioid receptor variation and alcohol dependence, Alcoholism: Clin Exp Res. 22:2108-110.
111. Sander T., Harms H., Dufeu P., et al., 1998, Serotonin transporter gene variants in alcohol-dependent subjects with dissocial personality disorder, Biol Psychiatry. 43:908-912.
112. Schinka J., Town T., Abdullah L., Crawford F., Ordorica P., Francis E. et al., 2002, A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances, Mol Psychiatry. 7:224-228.
113. Schuckit M. A., 1995, Alcohol-related disorders, in Comprehensive Textbook of Psychiatry 6th ed. (Kaplan HI and Sadok BJ eds) pp. 775-791, Plenum Press, New York.
114. Schuckit M. A., Mazzanti C, Smith T. L., 1999, elective genotyping for the role of 5-HT2A, 5-HT2C, und GABAAa6 receptors and the serotonin transporter in the level of response to alcohol: A pilot study, Biol. Psychiatry. 45:647-651.
115. Schumann G., Rujescu D., Kissling C, et al., 2003c, Analysis of genetic variations of protein tyrosine kinase fyn and their association with alcohol dependence in two independent cohorts, Biol Psychiatry. 54:1422-1426.
116. Schumann G., Rujescu D., Szegedi A., et al., 2003a, No association of alcohol dependence with a NMDA-receptor 2B gene variant, Mol Psychiatry. 8:11-2.
117. Schwitters S. Y., Johnson R. C., Johnson S. B., Ahern F. M., 1982b, Familial resemblances in flushing following alcohol use, Behavior Genetics. 12:349-352.
118. Schwitters S. Y., Johnson R. C., McClearn G. E., Wilson J. R., 1982a, Alcohol use and the flushing response in different racial groups, Journal of Studies on Alcohol. 43:1259-1262.
119. Shi J., Hui L., Xu Y., Wang F., Huang W., Hu G., 2002, Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin, Hum Mutat. Apr; 19(4):459-60.
120. Shippenberg T. S., Herz A., 1987, Place preference conditioning reveals the involvment of D1-dopamine receptors, in the motivational properties of μ- and K-opioid agonists, Brain Res. 436:169-172.
121. Slater S. J., Cox K. J. A., Lombardi J. V., et al., 1993, Inhibition of protein kinase C by alcohols and anaesthetics, Nature. 364:82-84.
122. Smith A. P., Lee N. M., 2003, Opioid receptor interactions: Local and nonlocal, symmetric and asymmetric, physical and functional, Life Sciences. 73:1873-1893.
123. Smolka M., Sander T., Schmidt L. G., Samochowiec J., Rommelspacher H., Gscheidel N., Wendel B., Hoehe M. R., 1999, Mu-opioid receptor variants and dopaminergic sensitivity in alcohol withdrawal, Psychoneuroendocrinology. Aug; 24(6):629-38.
124. Spanagel R., Bienkowski P., 2002, Glutamatergic mechanisms in alcohol dependence and addiction. in: Therapeutic Potential of Ionotropic Glutamate Receptor Antagonists and Modulators. In: Lodge D., Danysz W., Parsons F. P. (Hrsg) Graham Publishing Co., 375-403.
125. Spanagel R., Herz A., Shippenberg T. S., 1992, Opposing tonically active endogeneous opioid systems modulate the mesolimbic dopaminergic pathway, Proc Natl Acad Sci USA. 89:2046-2050.
126. Strowig A. B., 2000, Relapse determinants reported by men treated for alcohol addiction: the prominence of depressed mood, J Subst Abuse Treat. Dec; 19(4):469-74.
127. Szeto C, Tang M., Lee D., Stadlin A., 2001, Association between |I opioid receptor gene polymorphisms and Chinese heroin addicts, NeuroReport. 12:1103-1106.
128. Takeshita T., Morimoto K., Mao X. Q., Hashimoto T., Furuyama J., 1994, Characterization of the three genotypes of low Km aldehyde dehydrogenase in a Japanese population, Hum Genet. 94:217-223.
129. Tan E. C., Tan C. H., Karupathivan U., Yap E. P., 2003, |I opioid receptor gene polymorphisms and heroin dependence in Asian populations, Neuroreport. Mar. 24; 14(4):569-72.
130. Town T., Abdullah L., Crawford F., Schinka J., Ordorica P., Francis E. et al., 1999, Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency, Am J Med Genet. 88:458-461.
131. Tsai G., Coyle J. T., 1998, The role of glutamatergic neurotransmission in the pathophysiology of alcoholism, Annu Rev Med. 49:173-84.
132. Türker T., Sodmann R., Goebel U., et al., 1998, High ethanol tolerance in young adults is associated with the low-activity variant of the promoter of the human serotonin transporter gene, Neurosci Lett. 248:147-150.
133. Tyndale R. F., 2003, Genetics of Alcoholism and Tobacco Use in Humans, Annals of Medicine. 35:94-121.
134. Verheul R., Van Den Brink W., Geerlings P., 1999, A three-pathway psychobiological model of craving for alkohol, Alcohol Alcohol. 34:197-222.
135. Verlaan M., Te Morsche R. H., Roelofs H. M., Laheij R. J., Jansen J. B., Peters W. H., Drenth J. P., 2004, Genetic polymorphisms in alcohol-metabolizing enzymes and chronic pancreatitis, Alcohol Alcohol. Jan-Feb; 39(1):20-4.
136. Vidali M., Stewart S. F., Rolla R., Daly A. K., Chen Y., Mottaran E., Jones D. E., Leathart J. B., Day C. P., Albano E., 2003, Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease, Hepatology. Feb; 37(2):410-9.
137. Volpicelli J. R., 1987, Uncontrollable events and alcohol drinking, Br J Addict. 82:381-392.
138. Volpicelli J. R., Alterman A. I., Hayashida M., O'Brien C. P., 1992, Naltrexone in the treatment of alcohol dependence, Arch Gen Psychiatry. 49:876-880.
139. Volpicelli J. R., O'Brien C. P., Alterman A. I., Hayashida M., 1990, Naltrexone and the treatment of alcohol dependence: initial observations. In: Reid LD (ed) Opioids, Bulimia, and Alcohol Abuse & Addiction. Springer-Verlag: New York. pp 195-214.
140. Volpicelli J. R., Watson N. T., King A. C., Sherman C. E., O'Brien C. P., 1995, Effect of naltrexone on alcohol 'high' in alcoholics, Am J Psychiatry. 152:613-615.
141. Von Bardeleben U., Heuser I. J. E. and Holsboer F., 1989, Human CRH stimulation response during acute withdrawal and after medium-term abstention from alcohol abuse, Psychoneuroendocrinology. 14 pp. 441-449.
142. Wand G. S., Mangold D., El Deiry S., McCaul M. E., Hoover D., 1998, Family history of alcoholism and hypothalamic opioidergic activity, Arch Gen Psychiatry. 55:1114-1119.
143. Wand G. S., McCaul M., Yang X., Reynolds J., Gotjen D., Lee S. et al., 2002, The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade, Neuropsychopharmacology. 26:106-114.
144. Wang D., Quillan J. M., Winans K., Lucas J. L., Sadee W., 2001, Single nucleotide polymorphisms in the human μ opioid receptor gene alter basal G protein coupling and calmodulin binding, J Biol Chem. Sep. 14; 276(37):34624-30.
145. Wang J. B., Imai Y., Eppler C. M., Gregor P., Spivak C. E., Uhl G. R., 1993, μ opiate receptor: cDNA cloning and expression, Proc Natl Acad Sci USA. Nov. 1; 90(21):10230-4.
146. Weed M. R., Wolverton W. L, 1995, The reinforcing effects of dopamine D1-Receptor agonists in the rhesus monkeys, J Pharmacol Exp Ther. 275:1367-1374.
147. Wernicke C., Samochowiec J., Schmidt L. G., Winterer G., Smolka M., Kucharska-Mazur J., Horodnicki J., Gallinat J., Rommelspacher F., Polymorphisms in the N-methyl-D-aspartate receptor 1 and 2B subunits are associated with alcoholism-related traits, Biol Psychiatry. 2003 Nov. 1; 54(9):922-8.
148. Wise R. A., 1988, The neurobiology of craving: Implications for the understanding of addiction, J Abnorm Psychol. 97:118-132.
149. Yoshida A., Ikawa M., Hsu L. C., Tani K., 1985, Molecular abnormality and cDNA cloning of human aldehyde dehydrogenases. Alcohol. 2:103-10.